Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 3/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | DHODH | Q02127 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | RARB | P10826 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26075880 | 1.00 | PLA2G2A (0.41) | PLA2G2APTPN11MAPTDHODHKDM4E | |
| SCHEMBL26075868 | 1.00 | PLA2G2A (0.41) | PLA2G2APTPN11MAPTDHODHKDM4E | |
| SCHEMBL26075877 | 0.99 | PLA2G2A (0.41) | PLA2G2APTPN11MAPTDHODHKDM4E | |
| SCHEMBL26075867 | 0.97 | PLA2G2A (0.42) | PLA2G2AMAPTDHODHKDM4ENPC1 | |
| SCHEMBL26075866 | 0.93 | DHODH (0.43) | PLA2G2ADHODHPDE10A | |
| SCHEMBL26075247 | 0.90 | PDE2A (0.44) | PLA2G2APTPN11MAPTDHODHKDM4E | |
| SCHEMBL26075283 | 0.90 | PDE2A (0.44) | PLA2G2APTPN11MAPTDHODHKDM4E | |
| SCHEMBL26075965 | 0.90 | PDE2A (0.44) | PLA2G2APTPN11MAPTDHODHKDM4E | |
| SCHEMBL26075280 | 0.90 | PDE2A (0.44) | PLA2G2APTPN11MAPTDHODHKDM4E | |
| SCHEMBL26075902 | 0.89 | NCF1 (0.37) | PLA2G2ADHODHKDM4ENPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | PLA2G2A 1679/4885PTPN11 3866/4885MAPT 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.